CAR T-Cell Therapy vs. Bispecific Antibodies

Both of these treatments end the same way: a T cell kills a cancer cell. A T cell is a white blood cell whose job is to destroy diseased cells. What differs is how each treatment gets a T cell to do that job — and that difference drives the calendar, the travel, and the monitoring rules.

CAR T-cell therapy rebuilds a person's own T cells in a factory. Bispecific antibodies are ready-made drugs that grab a T cell and a cancer cell at the same moment. Both are used in lymphoma and multiple myeloma, so the two often come up in the same conversation.

The National Cancer Institute describes the steps. Blood is drawn, and the T cells are separated out. Those cells go to the maker's lab, where they are engineered to carry a new surface protein called a chimeric antigen receptor, or CAR. The CAR lets the cell latch onto an antigen — a marker protein — found on the cancer cells. The cells are then grown until there are hundreds of millions of them. That batch ships back to the hospital. It is given as a single infusion.

NCI puts the whole span, from the first blood collection to the infusion, at about 3 to 5 weeks. NCI lists seven approved CAR T products. Abecma and Carvykti treat multiple myeloma. Aucatzyl and Tecartus treat adult B-cell acute lymphoblastic leukemia, a cancer of young white blood cells. Kymriah treats that leukemia in children and young adults, plus two lymphomas. Breyanzi and Yescarta treat several lymphomas.

A bispecific antibody has two grabbing arms on one molecule. One arm holds CD3, a protein on T cells. The other holds a marker on the cancer cell. FDA labeling calls these drugs T-cell engagers, and the target names appear right in the label. Epcoritamab (Epkinly) is CD20-directed — CD20 sits on B-cell lymphoma cells. Teclistamab (Tecvayli) is BCMA-directed, and BCMA sits on myeloma cells.

Nothing is collected from the patient, so there is no wait for manufacturing. Both drugs above are given as shots under the skin.

Bispecific labels start with small "step-up" doses to blunt the immune reaction. The Epkinly label works in 28-day cycles. For large B-cell lymphoma, day 1 is a tiny dose, day 8 a larger one, and day 15 brings the first full dose. Follicular lymphoma adds a third step on day 15, with the full dose on day 22. Dosing then thins out over time, down to one dose per cycle from cycle 10 onward.

CAR T has no such ladder. It is one infusion, and there is no second one. The trade is a wait of several weeks while the cells are made, during which the cancer is still there and other treatment may be needed to hold it steady.

These are not general suggestions. They are printed instructions.

The Yescarta label sets three. Check the patient at least daily for 7 days after the infusion. Stay near a healthcare facility for at least 2 weeks. Do not drive for at least 2 weeks.

The Tecvayli label calls for a 48-hour hospital stay after step-up dose 1. It calls for another after step-up dose 2. After the first full dose, the label asks for daily checks near a healthcare facility for 48 hours.

Epkinly's rule has loosened. The 2023 approval label ordered a 24-hour hospital stay after the first full dose on cycle 1 day 15. The current label asks the team to judge whether hospital or outpatient care fits that dose. An older printout may carry a rule that has since changed.

On June 27, 2025, FDA ended the Risk Evaluation and Mitigation Strategy, or REMS, for six CAR T products: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. Two rules fell away. A hospital no longer has to be specially certified to give the product. It no longer has to keep two doses of tocilizumab on site for each patient. FDA said the boxed warning and the medication guide now carry the risk message well enough.

The bispecific side did not change in the same way. Tecvayli is still available only through a restricted program, the Tecvayli and Talvey REMS, and its label says so.

One requirement survived the 2025 change: makers must still run post-marketing safety studies that follow patients for 15 years, looking for second cancers. The Yescarta label states that T-cell cancers have occurred after treatment with CD19- and BCMA-directed CAR T products.

Every product named here carries a boxed warning for the same pair of problems.

Cytokine release syndrome (CRS) happens when the activated cells flood the blood with cytokines, the immune system's chemical messengers. NCI describes the result as dangerously high fevers and sharp drops in blood pressure. Severe CRS can be fatal, though that is rare. NCI says CRS is often controlled with tocilizumab, a drug that blocks the cytokine IL-6, plus steroids if needed.

Immune effector cell-associated neurotoxicity syndrome (ICANS) is the nerve-related reaction. NCI names confusion, unusual sleepiness, and trouble speaking as hallmark signs, and reports that steroids are the usual treatment. When steroids fall short, NCI notes studies of anakinra, an arthritis drug, both to treat ICANS and to blunt it when given soon after infusion.

The Yescarta label instructs teams to use continuous heart telemetry and pulse oximetry for grade 2 or higher CRS. That is the practical reason for the proximity rules above.

NCI's CAR T page does not compare the two approaches head to head, and neither the Yescarta, Epkinly, nor Tecvayli label names a preferred order between them. The labels define who each product is approved for and how many prior treatments are required first, and those numbers differ by product and by disease. Tecvayli shows how wide that gap can be. Used alone, it is approved only after four or more prior lines of therapy. Paired with daratumumab and hyaluronidase, it is approved after just one prior line.

The collection and infusion steps are walked through in CAR T-cell therapy. The two-armed molecule is covered in bispecific antibodies. Related immune reactions appear in immune-related side effects.

Whichever of the two you end up on, the risk window is the same and so is the response. With a bispecific it reopens at every step-up dose, not just at the start.

• Call 911 or go to an emergency department if breathing becomes laboured, you cannot be woken normally, a seizure occurs, or you collapse. Tell the crew which product you were given and on what date. That single fact changes their treatment.
• Ring your cell therapy team the instant a fever appears, whatever the time, or if you feel hot and shivery within a day or two of an infusion or injection. Both classes carry a boxed warning for cytokine release syndrome, your counts are usually low at the same moment, and this is treated with tocilizumab and steroids rather than watched overnight. Go to an emergency department if the team cannot be reached in a few minutes, and say which product you were given.
• Call your cell therapy team the same day if home blood pressure readings drop below your usual range.
• Call your cell therapy team the same day if a partner, parent or friend notices your speech slurring, your handwriting deteriorating, or unusual drowsiness or confusion. Those are the signs of the nerve-related reaction, and they can escalate within hours.
• Call your cell therapy team within a day or two if an infection seems slow to shift, you are unusually breathless on exertion, or you bruise or bleed more easily than before.

While a label tells you to stay near the treating facility and not to drive, treat that as part of the medicine rather than advice. It exists so that the calls above can be answered in minutes.

• NCI: CAR T cells
• NCI: T-cell transfer
• FDA: CAR T REMS ended
• DailyMed: Yescarta
• DailyMed: Tecvayli
• DailyMed: Epkinly